Back to Trades
Total Value
$8.2M
Net $8.2M sold
Filing Date
Jun 25, 2026
2 transactions
Sales
$8.2M
2 transactions
Trade Summary
On Jun 23, 2026, Hite Christopher, EVP & Chairman, Partnering, sold $8.2M of Royalty Pharma plc (RPRX) across 2 transactions. The filing covers Class A Ordinary Shares and reflects net selling of $8.2M. Reported prices ranged from $54.11 to $54.47. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Royalty Pharma plc
- Ticker Symbol
- RPRX
- CIK
- 0001802768
Insider Information
- Name
- Hite Christopher
- Role
- EVP & Chairman, Partnering
- Location
- NEW YORK, NY
Filing Details
- Filing Date
- Jun 25, 2026
- Transaction Date
- Jun 23, 2026
- Accession Number
- 0001814238-26-000009
- Form Type
- 4
- Net Trading Amount
- -$8.2M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jun 23, 2026 | Class A Ordinary Shares | 32,408 | $54.11 | Sale | $1.8M |
| Jun 23, 2026 | Class A Ordinary Shares | 117,592 | $54.47 | Sale | $6.4M |
Want live alerts when Hite Christopher trades again?
Download Insider Trades to track RPRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.
- (F2)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.39 to $54.38 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F3)The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $54.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.